Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumors
PPCB•Phase 1b trial plans and regulatory status
Timeline accelerated for a Phase 1b first-in-human trial in advanced solid tumors, with pancreatic cancer a priority; an Australian trial application is planned soon.
PRP, an intravenous pancreatic proenzyme combination, already holds FDA Orphan Drug Designation for pancreatic cancer.
Trial timeline accelerated after new PRP data
Propanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer models, not yet presented at a scientific meeting.
Studies showed strong tumor control, fewer metastases, longer survival, favorable tolerability signals, supporting a differentiated mechanism aimed at resistance.
